Shots:

• The P-III KEYNOTE-564 trial involves assessing Keytruda (200 mg- IV- on day1 of each 3wks. cycle for up to 17 cycles) as adjuvant therapy vs PBO in 950 patients with RCC- following nephrectomy and resection of metastatic lesions
• The study showed improvement in 1EPs i.e DFS while the trial will continue to evaluate its 2EPs i.e. OS. The safety profile was consistent with observed in previously reported studies
• Keytruda is currently approved in the US- EU and Japan in combination with axitinib as a 1L treatment for advanced RCC. The company continues to evaluate the therapy for other cancer treatments across multiple settings and stages of RCC through its broad clinical program

  Ref: Merck | Image: Merck